LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Rating of "Buy" by Brokerages

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have earned a consensus recommendation of "Buy" from the six analysts that are covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $46.60.

Several analysts recently issued reports on LENZ shares. Piper Sandler started coverage on shares of LENZ Therapeutics in a report on Monday, April 14th. They issued an "overweight" rating and a $51.00 price objective on the stock. HC Wainwright reissued a "buy" rating and issued a $38.00 price target on shares of LENZ Therapeutics in a research note on Wednesday, April 16th. Citigroup upped their price target on LENZ Therapeutics from $44.00 to $47.00 and gave the stock a "buy" rating in a research note on Thursday, March 20th. Finally, TD Cowen started coverage on LENZ Therapeutics in a research note on Tuesday, March 18th. They issued a "buy" rating and a $60.00 price objective for the company.

Institutional Investors Weigh In On LENZ Therapeutics

A number of large investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in LENZ Therapeutics during the fourth quarter worth approximately $29,000. SG Americas Securities LLC boosted its stake in shares of LENZ Therapeutics by 20.7% during the fourth quarter. SG Americas Securities LLC now owns 5,458 shares of the company's stock worth $158,000 after buying an additional 935 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of LENZ Therapeutics by 14.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,914 shares of the company's stock valued at $229,000 after purchasing an additional 1,005 shares during the last quarter. Rhumbline Advisers grew its position in LENZ Therapeutics by 6.2% in the 4th quarter. Rhumbline Advisers now owns 18,754 shares of the company's stock valued at $541,000 after buying an additional 1,100 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of LENZ Therapeutics by 162.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock valued at $54,000 after acquiring an additional 1,151 shares in the last quarter. 54.32% of the stock is owned by hedge funds and other institutional investors.

LENZ Therapeutics Price Performance

NASDAQ:LENZ opened at $25.97 on Wednesday. The company's 50-day moving average is $24.31 and its two-hundred day moving average is $27.29. LENZ Therapeutics has a 1-year low of $14.42 and a 1-year high of $38.93. The firm has a market capitalization of $715.34 million, a price-to-earnings ratio of -5.44 and a beta of 0.41.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04). As a group, equities analysts anticipate that LENZ Therapeutics will post -2.18 earnings per share for the current fiscal year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.